#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ornithine transcarbamoylase deficiency Infantile apnoea Ureteric cancer Neuroendocrine carcinoma Juvenile psoriatic arthritis Blastic plasmacytoid dendritic cell neoplasia Liver abscess Biliary cancer metastatic Vernal keratoconjunctivitis Colitis ulcerative Transitional cell carcinoma Systemic sclerosis pulmonary Metabolic disorder Solitary fibrous tumour Haemophilia A with anti factor VIII More trials…

    Learn about Rare Diseases

    Primary immunodeficiency syndrome – Diagnostics MELAS syndrome – Basic Information Sjogren’s syndrome Combined immunodeficiency – Diagnostics Amyotrophic lateral sclerosis – Trials in Disease Epidermolysis bullosa – Treatment Hyperoxaluria – Treatment Hereditary optic atrophy – Life with Disease Hereditary optic atrophy – Diagnostics Haemolytic uraemic syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    INSULIN DEGLUDEC Chloroprocaine Hydrochloride Omp12 Ergocalciferol Alfacalcidol R2R01 Bms-986442 Regn7257 Bexmarilimab NORGESTIMATE GSKVX000000070248 BGB-16673 Dexamethasone Base Orismilast Purified Egg Phospholipids TIFCEMALIMAB Atrasentan Hydrochloride Dasatinib Ly3537982 Cortisone More therapies…

    Learn about Your Condition

    Atrophic vulvovaginitis Phaeochromocytoma Keratosis follicular Pneumonia chlamydial Immunodeficiency congenital Reperfusion injury Thyroid cancer metastatic Peritoneal cancer index Bone sarcoma Primary hyperaldosteronism Alcoholism Hereditary ataxia Anogenital dysplasia Desmoplastic melanoma Hairy cell leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fundacion De La Comunitat Valenciana Para La Gestion…

Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante

Edificio Gris, Avenida Pintor Baeza 12, Alicante, 03010, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Mitoxantrone
    • Bortezomib
    • Dexamethasone
    Austria Belgium Czechia Finland France Germany +5

  • A study to compare using a half dose of iomeprol versus a standard dose of iomeprol for imaging lung tumors with spectral CT scans.

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Iomeprol
    Spain

  • Study on Pulmonary Embolism: Comparing Iomeprol Dosages in CT Scans for Patients with Suspected Pulmonary Embolism

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Iomeprol
    Spain

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!